Table 3 Univariate analysis of risk factors associated with locoregional recurrence (n = 121 case-control pairs)

MBD quartiles

 1, 2 (0– 50%)

82

69

26

1.0

 3 (50– 75%)

32

41

13

3.1

1.1–9.8

0.043^†

 4 (75– 100%)

7

11

4

5.7

1.2–34.9

0.048^†

Tumor size (mm)

 0–10

19

19

8

1.0

 10 − 19

19

22

12

2.5

0.6–10.1

0.187

 20 − 50

68

63

15

1.8

0.2–3.8

0.806

 >50

15

17

8

4.1

0.3–57.5

0.291

Positive axillary nodes

 None

47

49

15

1.0

 1–3

32

32

12

0.6

0.1–2.5

0.477

 >4

42

40

16

0.8

0.1–6.4

0.731

Margin

 Negative

112

106

37

1.0

 Positive

9

15

6

3.3

1.3–8.3

0.010^†

Adjuvant chemotherapy

 Yes

95

100

32

1.0

 No

26

21

11

2.0

0.7–5.3

0.166

Adjuvant hormone therapy

 Yes

74

71

22

1.0

 No

47

50

21

2.0

0.2–22.1

0.571

Adjuvant target therapy

 Yes

21

19

6

1.0

 No

100

102

37

6.5

0.0–56.5

0.471

Adjuvant radiotherapy

 Yes

62

57

20

1.0

 No

59

64

23

1.6

0.6–3.9

0.120

Triple-negative cancer

 Negative

100

95

34

1.0

 Positive

21

26

9

2.0

0.5–8.0

0.327

BMI (kg/m²)

 Normal (<25)

85

80

26

1.0

 Overweight (25–30)

28

33

13

1.2

0.6–2.4

0.708

 Obese (>30)

8

10

4

1.1

0.3–3.8

0.931